Perspectives of Systemic Lupus Erythematosus Therapy

被引:0
作者
Borysewicz, Krzysztof [1 ]
机构
[1] Silesian Piasts Univ Med, Dept Rheumatol & Internal Dis, PL-50556 Wroclaw, Poland
来源
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE | 2008年 / 17卷 / 04期
关键词
SLE; treatment; monoclonal antibodies; rituximab;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Although systemic lupus erythematosus (SLE) is a complex autoimmune disease of unknown origin, recent advances in our understanding of its pathogenesis have suggested new, targeted approaches to therapy. In this review the underlying scientific rationale and results of clinical studies of new treatment approaches to SLE are discussed with a focus on cell-depleting therapies and cytokine blockade. It has become clear that B lymphocytes play a key role in the disease's pathogenesis and aberrant interaction between B and T cells are critical to its emergence progression. New agents that directly target immune cells which are abnormal in SLE include B-cell-depleting (anti-CD20) and -modulating (anti-CD22) antibodies. Another promising approach is to block co-stimulatory interactions between T and B cell (CTLA-41g). Immune cells can also be manipulated indirectly through cytokine effects (anti-BAFF). Pro-inflammatory cytokines can be blocked in SLE (anti-TNF anti-IL-10). Most of the available data on these new treatment approaches item from open-label trials, but controlled trials are under-way (Adv Clin Exp Med 2008, 17, 4, 433-439).
引用
收藏
页码:433 / 439
页数:7
相关论文
共 50 条
[31]   Biologics in the treatment of systemic lupus erythematosus [J].
Lateef, Aisha ;
Petri, Michelle .
CURRENT OPINION IN RHEUMATOLOGY, 2010, 22 (05) :504-509
[32]   Treatment of systemic lupus erythematosus with epratuzumab [J].
Traczewski, Pawel ;
Rudnicka, Lidia .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (02) :175-182
[33]   Targeted therapies in systemic lupus erythematosus [J].
Grech, P. ;
Khamashta, M. A. .
LUPUS, 2013, 22 (10) :978-986
[34]   Biologicals for the treatment of systemic lupus erythematosus? [J].
Gunnarsson, Iva ;
van Vollenhoven, Ronald F. .
ANNALS OF MEDICINE, 2012, 44 (03) :225-232
[35]   THE TREATMENT OF SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
ALARCONSEGOVIA, D .
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1994, 12 :S49-S53
[36]   New developments in systemic lupus erythematosus [J].
Tsang-A-Sjoe, Michel W. P. ;
Bultink, Irene E. M. .
RHEUMATOLOGY, 2021, 60 :21-28
[37]   Ocular involvement in systemic lupus erythematosus [J].
Preble, Janine M. ;
Silpa-archa, Sukhum ;
Foster, C. Stephen .
CURRENT OPINION IN OPHTHALMOLOGY, 2015, 26 (06) :540-545
[38]   Modern therapy for systemic lupus erythematosus [Modernetherapie bei systemischem lupus erythematodes] [J].
Fischer-Betz R. ;
Schneider M. .
Zeitschrift für Rheumatologie, 2007, 66 (8) :662-671
[39]   Recent progress in conventional and biologic therapy for systemic lupus erythematosus [J].
Wofsy, David .
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 :66-68
[40]   Therapeutic peptides for the treatment of systemic lupus erythematosus: a place in therapy [J].
Talotta, Rossella ;
Atzeni, Fabiola ;
Laska, Magdalena Janina .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (08) :845-867